EGFR and neoplasm: The patient was given gefitinib at 250 mg/qd as a first-line treatment after identification of the epidermal growth factor receptor (EGFR) L858R mutation in a tumor biopsy sample using the amplification-refractory mutation system (Fig. 1A).